This PR is entirely appropriate, IMO -- after the

This PR is entirely appropriate, IMO -- after the scorn and contempt we endured from the FDA and in the big-pharma-connected press, this PR shows that that era is OVER and the FDA is serious about confirming LL's safety and efficacy in this first process. We're a PLAYER now (and should have been all along); it's not just 'any' meeting that happened with a normal drug in development. This is a crucial corrective turning point in a long and painful story.